Portal de Periódicos da CAPES

Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy

2023; American Medical Association; Volume: 80; Issue: 11 Linguagem: Inglês

10.1001/jamaneurol.2023.3400

2168-6157

Emanuele Cerulli Irelli, Enrico Cocchi, Alessandra Morano, Joanna Gesche, Roberto Caraballo, Simona Lattanzi, Gionata Strigaro, Cecilia Catania, Edoardo Ferlazzo, Angelo Pascarella, Sara Casciato, P. P. Quarato, Chiara Pizzanelli, Patrizia Pulitano, Loretta Giuliano, Veronica Viola, Barbara Mostacci, Francesco Fortunato, Carla Marini, Giancarlo Di Gennaro, Antonio Gambardella, Angelo Labate, Francesca Felicia Operto, Anna Teresa Giallonardo, Betül Baykan, Christoph P. Beier, Carlo Di Bonaventura, Daniela Fatuzzo, Eleonora Rosati, Giulio Pastorelli, Biagio Sancetta, Giovanni Assenza, Mario Tombini, Emanuela Viglietta, Pietro Pignatta, Vittoria Cianci, Irene Bagnasco, Edoardo Pronello, Marta Piccioli, Chiara Milano, Domenica Battaglia, Marco Perulli, Francesca Bisulli, Martina Fanella, Roberto De Simone, Giuseppe Pontrelli, Giovanni Boero, F. Gilio, F. Gragnani, Biagio Orlando, Adolfo Mazzeo, Chiara Panzini,

Hemoglobinopathies and Related Disorders

After the recent limitations to prescribing valproate, many studies have highlighted the challenging management of female patients of reproductive age with idiopathic generalized epilepsy (IGE). However, no study, to the authors' knowledge, has addressed the comparative effectiveness of alternative antiseizure medications (ASMs) in these patients.